Drug Search Results
More Filters [+]

Biolimus

Alternative Names: biolimus
Latest Update: 2024-11-01
Latest Update Note: Clinical Trial Update

Product Description

The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01137019)

Mechanisms of Action: Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Colombia | United Arab Emirates

Approved Indications: None

Known Adverse Events: None

Company: Biosensors Europe
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Biolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Myocardial Ischemia|Coronary Artery Disease|Myocardial Infarction|ST Elevation Myocardial Infarction|Acute Coronary Syndrome|Stroke|Thrombosis|Inflammation|Angina, Stable|Hypertension|Dyslipidemia

Phase 3: Myocardial Ischemia|Coronary Artery Disease|Coronary Disease

Phase 2: Coronary Thrombosis|ST Elevation Myocardial Infarction|Coronary Artery Disease|Myocardial Ischemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2024-02-008-H01

N/A

Not yet recruiting

Coronary Disease

2027-05-23

LEADERS FREE IV (RCT)

N/A

Not yet recruiting

Angina, Unstable|Angina, Stable|Angina Pectoris|Coronary Artery Disease|Acute Coronary Syndrome|Myocardial Ischemia

2026-08-01

ChiCTR2000041438

N/A

Recruiting

Coronary Disease

2025-12-31

JW-PM-DCB-2024

N/A

Not yet recruiting

Coronary Artery Disease|Myocardial Ischemia

2025-12-30

Recent News Events